CTRI/2026/01/100720尚未招募不适用
A Comparative Study to Evaluate the Efficacy and Safety of Tofacitinib and Methotrexate as Monotherapy versus their Combination in the Management of Rheumatoid Arthritis
Eras Lucknow Medical College Hospital1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年1月20日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Effectiveness of treatment evaluated by End Study Investigation and ACR20/ACR50/ACR70 response evaluation.
研究概览
简要总结
This Observational trial is being done to evaluate the efficacy and safety of Tofacitinib and Methotrexate as mono-therapy versus their combination, in the management of Rheumatoid Arthritis for post graduation thesis submission for the department of Pharmacology.
研究设计
- 研究类型
- Interventional
- 分配方式
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- All
入选标准
- •Age 18 or more than 18 years both males and females.
- •Diagnosis of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)[A score of greater than or equal to 6/10 confirms the diagnosis of Rheumatoid Arthritis].
排除标准
- •Any chronic systemic disease of liver, kidney, lungs and gastrointestinal tract.
- •Other joint diseases (e.g. Osteoarthritis, Gout, Ankylosing Spondylitis) Severely immuno-compromised patient.
- •Pregnant or breastfeeding women.
- •Patient having contraindication for methotrexate(e.g. chronic liver disease, Bone marrow suppression, Active infections, Severe renal impairment).
结局指标
主要结局
Effectiveness of treatment evaluated by End Study Investigation and ACR20/ACR50/ACR70 response evaluation.
时间窗: 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk and 24 weeks.
次要结局
未报告次要终点
研究者
Singh Shashikumar Jitendra
Eras Lucknow Medical college and hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT07411586M.D. Anderson Cancer Center32
招募中
2 期
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after initial treatment with osimertinib.2024-512564-58-00AstraZeneca AB135
招募中
1 期
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerNCT07318324M.D. Anderson Cancer Center31
尚未招募
4 期
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)Alopecia AreataNCT07406204Hayat Abad Medical Complex, Peshawar78
尚未招募
2 期
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant ChemotherapyBreast CancerNCT07410234Tianjin Medical University Cancer Institute and Hospital110